Vera Therapeutics (NASDAQ:VERA – Free Report) had its price target decreased by HC Wainwright from $125.00 to $90.00 in a research note released on Wednesday, Marketbeat.com reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Vera Therapeutics’ Q3 2026 earnings at ($1.64) EPS, Q4 2026 earnings at […]

Eikon Therapeutics (NASDAQ:EIKN – Get Free Report) had its price objective dropped by stock analysts at Wedbush from $5.00 to $4.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has an “underperform” rating on the stock. Wedbush’s target price would indicate a potential downside of 59.90% from the stock’s previous […]

Vera Therapeutics (NASDAQ:VERA – Free Report) had its price objective cut by Wedbush from $43.00 to $34.00 in a research note published on Tuesday,Benzinga reports. They currently have a neutral rating on the stock. A number of other brokerages have also recently commented on VERA. Guggenheim increased their price target on shares of Vera Therapeutics […]

Ceva (NASDAQ:CEVA – Free Report) had its price target trimmed by Oppenheimer from $42.00 to $38.00 in a research report sent to investors on Tuesday, Marketbeat Ratings reports. The firm currently has an outperform rating on the semiconductor company’s stock. A number of other analysts have also recently weighed in on the stock. Benchmark assumed […]

Axsome Therapeutics (NASDAQ:AXSM – Free Report) had its target price raised by Needham & Company LLC from $267.00 to $268.00 in a research report sent to investors on Tuesday morning, MarketBeat Ratings reports. They currently have a buy rating on the stock. Several other equities research analysts have also issued reports on the stock. Morgan […]